Qiming Venture Partners

Qiming Venture Partners Becomes a UN PRI Signatory

Retrieved on: 
Monday, February 26, 2024
Investment, Socially responsible investing, Growth, Female, ESG, Principles for Responsible Investment, Health care, Partner, United Nations, Patient, Environment, Consumer, PRI, Robotics, Qiming Venture Partners, Renewable energy

Shanghai, Feb. 25, 2024 /PRNewswire/ -- China's leading venture capital firm Qiming Venture Partners announced its recent signing of the United Nations-supported Principles for Responsible Investment (PRI).

Key Points: 
  • Shanghai, Feb. 25, 2024 /PRNewswire/ -- China's leading venture capital firm Qiming Venture Partners announced its recent signing of the United Nations-supported Principles for Responsible Investment (PRI).
  • "The signing is a testimony to our commitment to Environmental, Social, and Governance (ESG) values as we practice responsible investment," said Duane Kuang, Founding Managing Partner of Qiming Venture Partners.
  • "PRI provides us with a robust framework that integrates sustainability and ethical considerations into our investment and decision-making process.
  • Within two primary sectors of investment - Technology & Consumer and Healthcare, Qiming proactively seeks investments in businesses that uphold and implement ESG values.

Leapstack has raised nearly 200 million RMB in Series C+ Funding, building a diversified technological value chain for health insurance

Retrieved on: 
Thursday, January 18, 2024
Cloud computing, Harman International, Policy, City, Insurance, Attention, Intelligence, Long-term care, Government, Legend Holdings, Qiming Venture Partners, Urbanization, Ageing, RPA, DCM, Growth, Risk management

In this context, the insurance industry, especially health insurance, is undergoing the digital transformation, with an active participation of technology enterprises in becoming more "automated."

Key Points: 
  • In this context, the insurance industry, especially health insurance, is undergoing the digital transformation, with an active participation of technology enterprises in becoming more "automated."
  • It pioneers the model of "digital risk control for health insurance," effectively facilitating the digital integration of policy-based medical insurance and commercial health insurance.
  • As Leapstack empowers digital services in government medical insurance and commercial insurance through technological advancements, it is concurrently pursuing expansion into the medical care and health industry.
  • Through these efforts, Leapstack remains committed to becoming a world-class technology platform for insurance, leveraging technologies to safeguard health guarantee.

Qiming Venture Partners' Portfolio Company UBTech Listed on Hong Kong Stock Exchange

Retrieved on: 
Friday, December 29, 2023
Partner, Qiming Venture Partners, Research, Education, IPO, HK, SLAM, History

Qiming is UBTech's early institutional investor, exclusively investing in its Series A round in 2015

Key Points: 
  • Qiming is UBTech's early institutional investor, exclusively investing in its Series A round in 2015
    SHANGHAI, Dec. 29, 2023 /PRNewswire/ -- Qiming Venture Partners' portfolio company UBTech, a humanoid robot leader in China, successfully debuted on the Hong Kong Stock Exchange today.
  • The first humanoid robot company to list on the exchange, UBTech (SEHK:9880)'s issue price was HK$90.00 per share, valuing it at HK$37.60 billion.
  • As an early institutional investor in UBTech, Qiming has been a key supporter since exclusively investing in its Series A financing in 2015.
  • Established in March 2012, UBTech is one of the few market players in the global humanoid robot industry.

Qiming Venture Partners' Portfolio Company UBTech Listed on Hong Kong Stock Exchange

Retrieved on: 
Friday, December 29, 2023
Partner, Qiming Venture Partners, Research, Education, IPO, HK, SLAM, History

Qiming is UBTech's early institutional investor, exclusively investing in its Series A round in 2015

Key Points: 
  • Qiming is UBTech's early institutional investor, exclusively investing in its Series A round in 2015
    SHANGHAI, Dec. 29, 2023 /PRNewswire/ -- Qiming Venture Partners' portfolio company UBTech, a humanoid robot leader in China, successfully debuted on the Hong Kong Stock Exchange today.
  • The first humanoid robot company to list on the exchange, UBTech (SEHK:9880)'s issue price was HK$90.00 per share, valuing it at HK$37.60 billion.
  • As an early institutional investor in UBTech, Qiming has been a key supporter since exclusively investing in its Series A financing in 2015.
  • Established in March 2012, UBTech is one of the few market players in the global humanoid robot industry.

Atantares has Completed Two Rounds of RMB100 Million Financing, and the Pre-A Round is led by Asia Green Fund

Retrieved on: 
Wednesday, August 2, 2023
Molecular biology, DNA, Qiming Venture Partners, Biotechnology, Recycling, CMOS, R, D, Fine chemical

BEIJING, Aug. 2, 2023 /PRNewswire/ -- Recently, Atantares announced the completion of Pre-A and Pre-A+ financing all around RMB100 million.

Key Points: 
  • BEIJING, Aug. 2, 2023 /PRNewswire/ -- Recently, Atantares announced the completion of Pre-A and Pre-A+ financing all around RMB100 million.
  • The Pre-A round is led by Asia Green Fund, followed by Fosun Health Capital and existing investors Frees Fund, Qiming Venture Partners, Next Capital, and NeuX Capital; Pre-A+ is exclusively invested by Alibaba Health.
  • The fund will mainly go towards the R&D of products, service operation, and capacity expansion.
  • Founded in 2021, Atantares' vision is to develop molecular chips by using integrated circuits or other semiconductor technologies to drive the semiconductor of biotechnology.

LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases

Retrieved on: 
Wednesday, May 31, 2023
Biotechnology, Pharmaceutical, Finance, Oncology, Health, Professional Services, Genetics, Clinical Trials, Shunwei Capital, Qiming Venture Partners, Clinical trial, Cancer, Bone marrow, Research, Immunotherapy, Lightspeed Venture Partners, LTZ, Entrepreneurship, Therapy, Tumor microenvironment, Cryptocurrency, Pharmaceutical industry

The closing of this round brings LTZ’s total funding to approximately $30 million since the company was founded in 2022.

Key Points: 
  • The closing of this round brings LTZ’s total funding to approximately $30 million since the company was founded in 2022.
  • The proceeds from this round of funding will be used to continue establishing the company’s platform and pipeline and building LTZ's global operations team.
  • “LTZ has made significant progress, both scientifically and operationally, since it was established last year,” said Robert Li, Ph.D., Co-Founder and CEO of LTZ.
  • “The LTZ team is taking a next-generation immunotherapy approach in treating cancer and autoimmune diseases, where there’s a high unmet need,” said Rui Li, Partner at Shunwei Capital.

Account Labs Emerges from UniPass and Keystone Merger, Forging Ahead in Web3 Account Abstraction

Retrieved on: 
Saturday, May 20, 2023
Ethereum, Bitcoin, Lixin, Qiming Venture Partners, Research, QR, DKIM, Capital, Architecture, Ecosystem, MetaMask, Cryptocurrency, Web3, Keystone, Web 2.0

This union is a strategic decision to leverage their combined expertise and focus on pioneering a world-class Web3 Account Abstraction solution.

Key Points: 
  • This union is a strategic decision to leverage their combined expertise and focus on pioneering a world-class Web3 Account Abstraction solution.
  • Account Labs reassures that post-merger, both Keystone and UniPass brands, along with their respective user bases, will be preserved.
  • Lixin shares his excitement about establishing Account Labs with Zhi Xian, looking forward to a swift expansion towards Account Abstraction.
  • Account Labs is poised to take on this challenge, promising to safeguard Web3 account security and promote widespread application of account abstraction, opening doors to the Web3 world for many more people."

Qiming Venture Partners Nisa Leung and Duane Kuang Made the 2023 Forbes Midas List

Retrieved on: 
Friday, May 5, 2023
Venus, Cloud, Roborock, Forbes China Celebrity 100, Female, Qiming Venture Partners, Midas List, Gan, CYG, Gold, Investment, CanSino Biologics, Mobile robot, T&C, VC, WeRide, Duane, Unisound, Pharmaceutical industry

SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.

Key Points: 
  • SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.
  • Qiming Venture Partners Managing Partner Nisa Leung and Founding Managing Partner Duane Kuang made the list.
  • Nisa Leung has become a Forbes Midas Lister for the fifth year in a row, placing 41st this year.
  • Duane Kuang made the Forbes Midas List for the fourth time, ranking 70th this year.

Qiming Venture Partners Nisa Leung and Duane Kuang Made the 2023 Forbes Midas List

Retrieved on: 
Friday, May 5, 2023
Venus, Cloud, Roborock, Forbes China Celebrity 100, Female, Qiming Venture Partners, Midas List, Gan, CYG, Gold, Investment, CanSino Biologics, Mobile robot, T&C, VC, WeRide, Duane, Unisound, Pharmaceutical industry

SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.

Key Points: 
  • SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.
  • Qiming Venture Partners Managing Partner Nisa Leung and Founding Managing Partner Duane Kuang made the list.
  • Nisa Leung has become a Forbes Midas Lister for the fifth year in a row, placing 41st this year.
  • Duane Kuang made the Forbes Midas List for the fourth time, ranking 70th this year.

Qiming Venture Partners' portfolio company MedSci successfully listed on HKEX main board

Retrieved on: 
Thursday, April 27, 2023
Communication, IPO, Omnichannel, MAU, Life, Big data, Qiming Venture Partners, Research, RWS, Patient, Physician, Series, Knowledge, AI, Development, Hong Kong Stock Exchange, HK, Nursing, Pharmaceutical industry

SHANGHAI, April 27, 2023 /PRNewswire/ -- On April 27th Beijing time, Qiming Venture Partners' portfolio company MedSci Healthcare Holdings Limited("MedSci"), a leading physician digital platform in China, successfully listed on the main board of Hong Kong Stock Exchange.

Key Points: 
  • SHANGHAI, April 27, 2023 /PRNewswire/ -- On April 27th Beijing time, Qiming Venture Partners' portfolio company MedSci Healthcare Holdings Limited("MedSci"), a leading physician digital platform in China, successfully listed on the main board of Hong Kong Stock Exchange.
  • As of the IPO, Qiming was one of the major investors of MedSci.
  • MedSci's successful listing is also the sixth IPO that Qiming has welcomed since 2023.
  • MedSci has always been focused on this area and played an important role in the industry's development.